Santhera Publishes Agenda for its Annual General Meeting

Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [3] - The company holds an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, for all indications worldwide, which is being investigated as an alternative treatment for Duchenne muscular dystrophy (DMD) [3] - AGAMREE has received regulatory approvals in multiple regions, including the U.S., EU, UK, China, and Hong Kong [3] Annual General Meeting (AGM) Details - The AGM is scheduled for May 20, 2025, at 10:00 CEST in Pratteln, Switzerland [1] - Registered shareholders will receive the invitation by mail, and the agenda will be available on the company's website [1] AGM Agenda Items - Approval of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements for 2024 [5] - Appropriation of the Annual Result and Offset of Deficit [5] - Consultative Vote on the Compensation Report for 2024 [5] - Discharge of the Board of Directors and Executive Management from Liability for the Financial Year 2024 [5] - Conditional Capital for Employee Participations and Amendment to the Articles of Incorporation [5] - Election of a new Member and Re-election of two Members of the Board of Directors, including the Chairman [5] - Re-election of the Members of the Nomination & Compensation Committee [5] - Approval of the Compensation for the Members of the Board of Directors and Executive Management [5] - Re-election of the Statutory Auditors and Independent Proxy [5]